Gujarat Themis expands into CDMO

Gujarat Themis Biosyn’s latest deal shows a specific route by which an older fermentation-focused Indian drugmaker is trying to widen into outsourced development and manufacturing. On May 22, 2026, the company said it had signed a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. through a Japan-incorporated wholly owned vehicle. GTBL said the purchase would add microbial research, development and manufacturing capabilities that go beyond its existing base in fermentation intermediates and active pharmaceutical ingredients. The company paired that move with a separate Sanofi brand acquisition announced earlier in 2026, giving the expansion both a services leg and a branded-products leg. ### Where did Gujarat Themis start before these acquisitions? Gujarat Themis Biosyn described itself in company materials as a pharmaceutical company with established capabilities in fermentation-based intermediates and APIs. Third-party filings and investor-document aggregators describe its core products as fermentation-based bulk drugs and intermediates including rifampicin intermediates and lovastatin, produced from its Vapi, Gujarat base. (bseindia.com) May 22, 2026 matters because GTBL itself framed the MicroBiopharm transaction as part of a “long-term strategy to evolve from a fermentation-led intermediates business” into a technology-driven CDMO platform. That wording is important because it came from the company’s exchange-filed press release rather than market commentary. (bseindia.com) ### What exactly does MicroBiopharm Japan add? MicroBiopharm Japan brings a different mix of activities than a plain intermediate supplier. GTBL said MBJ has more than six decades of experience in fermentation, microbial-based research, development and manufacturing of pharmaceuticals and specialty chemicals, and that it operates “from manufacturing proprietary pharmaceuticals to CDMO services.” (bseindia.com) Estimated FY26 revenue at MBJ was JPY 9.5 billion, or about 57 billion rupees, according to GTBL’s filing. Trade coverage citing the company said MBJ’s proprietary portfolio includes oncology, immunosuppressants, antibiotics and peptides, while its CDMO work spans small molecules and biologics, including recombinant proteins. (bseindia.com) ### Why does this move push Gujarat Themis toward CDMO work? The acquisition structure itself answers part of that question. GTBL said the MBJ purchase would be executed through a wholly owned special purpose vehicle in Japan and described the deal as accelerating its transition to a “fermentation-based globally integrated CDMO platform.” (bseindia.com) A second GTBL presentation said the MicroBiopharm deal would bring “additional manufacturing muscle, R&D capabilities, biotech know-how and access to key new customers and geographies,” and said the transaction would further its expansion into a CDMO. That gives the clearest company-stated rationale for why MBJ matters beyond simple capacity addition. (bseindia.com) ### How does the Sanofi deal fit alongside the Japan acquisition? April 23, 2026 is the other date to watch. CARE Ratings, in a July 15 representation reproduced in GTBL’s exchange filing, said the company had announced two acquisition plans: the MBJ purchase and an asset purchase agreement with Sanofi for anti-tuberculosis and anti-infective brands and associated trademark rights for 158 million euros. (nsearchives.nseindia.com) Sanofi’s portfolio gives GTBL a branded-pharma element that is different from contract manufacturing. Trade reports on the company filing said the package covered 13 branded generic products across more than 55 countries. Put together, the two deals show GTBL buying one asset for technology and CDMO capability and another for marketed brands. (bseindia.com) ### What does this mean for the kind of work the company can house? The company’s own disclosures point to three operating layers. GTBL’s legacy base remains fermentation-led intermediates and APIs; MBJ adds microbial R&D, precision fermentation-style capabilities and CDMO services; and the Sanofi transaction adds a portfolio of anti-infective brands that requires commercial, regulatory and supply-chain management across multiple markets. (indianpharmapost.com) That mix implies demand for roles across upstream fermentation, downstream processing, technology transfer, quality systems, regulatory filings and commercial operations, though GTBL has not publicly broken out a hiring plan in the materials reviewed. The company said the MBJ transaction is expected to close in Q2 FY27, while CARE’s July note said the Sanofi portfolio purchase would follow the Japan acquisition. (bseindia.com)